GAITHERSBURG, Md. & HAWTHORNE, N.Y.--(BW HealthWire)--July 3, 2001--Gene Logic Inc. (Nasdaq: GLGC - news), an integrated biological information and bioinformatics company, announced today that PsychoGenics, Inc., a biotechnology company focused on behavioral and neurological disorders, has subscribed to a CustomSuite of the GeneExpress® Suite, and has entered into a content collaboration focused on central nervous system (CNS) tissue samples.
Financial terms of the subscription agreement and content collaboration were not disclosed.
PsychoGenics will establish an entry level subscription to Gene Logic's GeneExpress® Suite through a CustomSuite subscription, which will include a customized subset of gene expression information focused on CNS disorders, and will apply this gene expression information toward its ongoing CNS-oriented research and development programs. The subscription agreement provides for broad deployment of the CustomSuite data across all of PsychoGenic's research divisions and includes access to the GeneExpress® Software System, Gene Logic's comprehensive data management, mining, analysis and visualization platform.
PsychoGenics Overview
PsychoGenics is a biotechnology company dedicated to improving treatments for behavioral and neurological disorders. The company's mission is to become a leader in behavioral neurobiology and its business strategy is to apply technology platforms including, proprietary, high throughput in vivo behavioral assay systems with associated bioinformatics, in partnership with pharmaceutical and biotechnology companies, to improve the efficiency and success rate with which drug candidates are discovered and targets are validated... |
